SHIFT Newsroom · GLOBAL
MASH fibrosis: an expert review of resmetirom and semaglutide
This international expert-panel review discusses resmetirom and semaglutide for MASH and fibrosis in the regulatory context covered by its authors. It is not a new comparative trial. Current UK product authorisation, eligibility and NHS access need separate official verification.
What the source says
This international expert-panel review discusses resmetirom and semaglutide for MASH and fibrosis in the regulatory context covered by its authors. It is not a new comparative trial. Current UK product authorisation, eligibility and NHS access need separate official verification.
Evidence and limits
The panel brings together phase 3 trial data, US product labels and clinical experience. It discusses diagnosis, treatment choice and monitoring in that context. This does not independently establish a current UK label, NHS pathway or treatment recommendation.
What we checked
We checked the primary publication record and available abstract. The full paper and supplements have not been reviewed for this correction.
SHIFT’s take
UK authorisation and NHS access must be checked separately against current official sources. An international expert review is not a UK treatment approval.
Known facts
- This international expert-panel review discusses resmetirom and semaglutide for MASH and fibrosis in the regulatory context covered by its authors.